{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Placebo+Tablets", "query": { "intervention": "Matching Placebo Tablets" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 2107, "total_pages": 211, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Matching+Placebo+Tablets&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-03T10:49:12.670Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00791778", "title": "Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Ovarian Neoplasms" ], "interventions": [ { "name": "Sorafenib (Nexavar, BAY43-9006)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 246, "start_date": "2008-11", "completion_date": "2012-12", "has_results": true, "last_update_posted_date": "2015-09-28", "last_synced_at": "2026-09-03T10:49:12.670Z", "location_count": 4, "location_summary": "La Jolla, California • Jacksonville, Florida • Augusta, Georgia + 1 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Augusta", "state": "Georgia" }, { "city": "Scarborough", "state": "Maine" } ], "official_url": "https://clinicaltrials.gov/study/NCT00791778" }, { "nct_id": "NCT00259376", "title": "American-Australian-African Trial With Dronedarone in Patients With Atrial Fibrillation or Atrial Flutter for the Maintenance of Sinus Rhythm", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Atrial Fibrillation", "Atrial Flutter" ], "interventions": [ { "name": "Dronedarone (SR33589)", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": null, "sex": "ALL", "summary": "21 Years and older" }, "enrollment_count": 629, "start_date": "2001-11", "completion_date": "2003-09", "has_results": false, "last_update_posted_date": "2010-02-15", "last_synced_at": "2026-09-03T10:49:12.670Z", "location_count": 1, "location_summary": "Bridgewater, New Jersey", "locations": [ { "city": "Bridgewater", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00259376" }, { "nct_id": "NCT01164579", "title": "Effects of Tofacitinib (CP-690,550) on Magnetic Resonance Imaging (MRI)- Assessed Joint Structure In Early Rheumatoid Arthritis (RA)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Rheumatoid Arthritis" ], "interventions": [ { "name": "Tasocitinib plus Methotrexate", "type": "DRUG" }, { "name": "Tofacitinib plus placebo methotrexate", "type": "DRUG" }, { "name": "Placebo tofacitinib plus Methotrexate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 109, "start_date": "2010-10", "completion_date": "2013-11", "has_results": true, "last_update_posted_date": "2015-04-22", "last_synced_at": "2026-09-03T10:49:12.670Z", "location_count": 8, "location_summary": "Gilbert, Arizona • Huntington Beach, California • Upland, California + 5 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Huntington Beach", "state": "California" }, { "city": "Upland", "state": "California" }, { "city": "Ormond Beach", "state": "Florida" }, { "city": "Pinellas Park", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01164579" }, { "nct_id": "NCT04334148", "title": "Healthcare Worker Exposure Response and Outcomes of Hydroxychloroquine", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "COVID-19" ], "interventions": [ { "name": "Hydroxychloroquine", "type": "DRUG" }, { "name": "Placebo oral tablet", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Adrian Hernandez", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 1360, "start_date": "2020-04-22", "completion_date": "2021-01-09", "has_results": true, "last_update_posted_date": "2021-10-12", "last_synced_at": "2026-09-03T10:49:12.670Z", "location_count": 34, "location_summary": "Aurora, Colorado • Gainesville, Florida • Jacksonville, Florida + 27 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Leesburg", "state": "Florida" }, { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04334148" }, { "nct_id": "NCT02147197", "title": "A Study of the Efficacy and Safety of a 3-month Treatment Course of Ulipristal Acetate for the Treatment of Abnormal Uterine Bleeding Associated With Leiomyomas", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Leiomyoma", "Uterine Hemorrhage" ], "interventions": [ { "name": "Ulipristal acetate (UPA)", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Allergan", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "FEMALE", "summary": "18 Years to 50 Years · Female only" }, "enrollment_count": 157, "start_date": "2014-03-31", "completion_date": "2016-03-29", "has_results": true, "last_update_posted_date": "2019-04-30", "last_synced_at": "2026-09-03T10:49:12.670Z", "location_count": 28, "location_summary": "Tucson, Arizona • San Diego, California • Denver, Colorado + 23 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "San Diego", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Lakewood", "state": "Colorado" }, { "city": "Milford", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT02147197" }, { "nct_id": "NCT01742208", "title": "Safety and Efficacy of Sotagliflozin (LX4211) in Patients With Inadequately Controlled Type 1 Diabetes Mellitus", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Type 1 Diabetes Mellitus" ], "interventions": [ { "name": "Sotagliflozin", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Lexicon Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 36, "start_date": "2013-02", "completion_date": "2014-01", "has_results": true, "last_update_posted_date": "2020-02-12", "last_synced_at": "2026-09-03T10:49:12.670Z", "location_count": 7, "location_summary": "Aurora, Colorado • Atlanta, Georgia • Baton Rouge, Louisiana + 4 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Baton Rouge", "state": "Louisiana" }, { "city": "Omaha", "state": "Nebraska" }, { "city": "The Bronx", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01742208" }, { "nct_id": "NCT04193176", "title": "Efficacy and Safety of Gefapixant (MK-7264) in Women With Chronic Cough and Stress Urinary Incontinence (MK-7264-042)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Cough" ], "interventions": [ { "name": "Gefapixant", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 376, "start_date": "2020-05-10", "completion_date": "2022-09-02", "has_results": true, "last_update_posted_date": "2024-11-05", "last_synced_at": "2026-09-03T10:49:12.670Z", "location_count": 19, "location_summary": "Paramount, California • Jupiter, Florida • Miami, Florida + 16 more", "locations": [ { "city": "Paramount", "state": "California" }, { "city": "Jupiter", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Sweetwater", "state": "Florida" }, { "city": "Winter Park", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT04193176" }, { "nct_id": "NCT01108510", "title": "Safety and Efficacy of COBI-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered With Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "HIV", "HIV Infections" ], "interventions": [ { "name": "COBI", "type": "DRUG" }, { "name": "RTV", "type": "DRUG" }, { "name": "ATV", "type": "DRUG" }, { "name": "FTC/TDF", "type": "DRUG" }, { "name": "COBI placebo", "type": "DRUG" }, { "name": "RTV placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 698, "start_date": "2010-04", "completion_date": "2015-04", "has_results": true, "last_update_posted_date": "2016-05-23", "last_synced_at": "2026-09-03T10:49:12.670Z", "location_count": 64, "location_summary": "Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 42 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Little Rock", "state": "Arkansas" }, { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01108510" }, { "nct_id": "NCT03911713", "title": "A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Cystic Fibrosis" ], "interventions": [ { "name": "VX-561", "type": "DRUG" }, { "name": "IVA", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Vertex Pharmaceuticals Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 77, "start_date": "2019-04-17", "completion_date": "2020-08-20", "has_results": true, "last_update_posted_date": "2022-01-25", "last_synced_at": "2026-09-03T10:49:12.670Z", "location_count": 30, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Long Beach, California + 25 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Long Beach", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Denver", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT03911713" }, { "nct_id": "NCT00688376", "title": "Efficacy and Safety of Donepezil Hydrochloride in Preadolescent and Adolescent Children With Attention Impairment Following Cancer Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Attention Impairment" ], "interventions": [ { "name": "Donepezil hydrochloride", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Eisai Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "6 Years to 17 Years" }, "enrollment_count": 72, "start_date": "2008-07-02", "completion_date": "2009-05-26", "has_results": true, "last_update_posted_date": "2022-01-05", "last_synced_at": "2026-09-03T10:49:12.670Z", "location_count": 13, "location_summary": "Stanford, California • Miami, Florida • Minneapolis, Minnesota + 10 more", "locations": [ { "city": "Stanford", "state": "California" }, { "city": "Miami", "state": "Florida" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "St Louis", "state": "Missouri" }, { "city": "New Brunswick", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT00688376" } ] }